Mayo Clinic

Neurologists at the Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting welcomed the introduction of the first US Food and Drug Administration-approved anti-amyloid antibody for early Alzheim

After many attempts and failures to bring a disease-modifying therapy forward for Alzheimer’s disease, the triumph of Eisai Co., Ltd. / Biogen, Inc. ’s amyloid protofibril-clearing antibody lecanemab

Two more small biopharmaceutical companies managed to launch initial public offerings recently, bringing the 2022 total to 17 drug developers that have gone public in the US this year, despite the fac

Scrip regularly reviews technology transfer activity across the biopharmaceutical sector. This edition of Tech Transfer Roundup focuses on oncology deals; the next edition will look at non-oncology de